A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH.
Concentrations of somatostatin and corticotrophin releasing hormone (CRH), measured in cerebrospinal fluid (CSF) have been reported to be low in suicidal patients with major depressive disorder (MDD). Often have MDD patients in general, high CSF-CRH and low CSF-somatostatin concentrations, which both seem to normalise with clinical recovery. The present study was designed to look for CSF-CRH and CSF-somatostatin alterations along with clinical changes in patients studied repeatedly after a suicide attempt. Sixteen patients with different diagnoses, initially inpatients after a suicide attempt (baseline), participated. Lumbar punctures and ratings according to the Suicidal Assessment Scale (SUAS) and the Montgomery-Asberg Depression Rating Scale (MADRS) were performed while patients were drug-free (baseline) and after a median of 7 (5 to 9) months. At follow up MADRS- and SUAS-scores were significantly decreased (P<0.05), whereas CSF-somatostatin was significantly increased (P=0.013) and CSF-CRH had not changed significantly. Thus, the patients showed long-lasting low CSF-CRH concentrations, in spite of changed CSF-somatostatin concentrations and clinical amelioration.
Westrin
A
A
Department of Clinical Neuroscience, Division of Psychiatry, Lund University, Lund, Sweden.
Ekman
R
R
Regnéll
G
G
Träskman-Bendz
L
L
D000328:Adult; D003346:Corticotropin-Releasing Hormone / Q000134:cerebrospinal fluid*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D013004:Somatostatin / Q000134:cerebrospinal fluid*; D013406:Suicide, Attempted
D013004:Somatostatin; D003346:Corticotropin-Releasing Hormone